Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)‘s stock had its “positive” rating reiterated by stock analysts at Leerink Swann in a note issued to investors on Tuesday, The Fly reports. They currently have a $552.00 target price on the biopharmaceutical company’s stock, down from their prior target price of $580.00. Leerink Swann’s price objective points to a potential upside of 16.32% from the stock’s current price.

Other analysts also recently issued research reports about the stock. UBS AG set a $489.00 price objective on shares of Regeneron Pharmaceuticals and gave the company a “buy” rating in a report on Friday, May 5th. Canaccord Genuity set a $522.00 price objective on shares of Regeneron Pharmaceuticals and gave the company a “buy” rating in a report on Monday. BMO Capital Markets increased their price objective on shares of Regeneron Pharmaceuticals from $412.00 to $421.00 and gave the company a “hold” rating in a report on Monday, May 15th. Piper Jaffray Companies increased their price objective on shares of Regeneron Pharmaceuticals from $446.00 to $557.00 and gave the company an “overweight” rating in a report on Tuesday, June 20th. Finally, Goldman Sachs Group, Inc. (The) reiterated a “neutral” rating and issued a $472.00 price objective (up previously from $469.00) on shares of Regeneron Pharmaceuticals in a report on Wednesday, August 9th. Two investment analysts have rated the stock with a sell rating, fourteen have issued a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus target price of $488.23.

Regeneron Pharmaceuticals (NASDAQ:REGN) opened at 474.54 on Tuesday. The stock has a market cap of $50.32 billion, a price-to-earnings ratio of 47.61 and a beta of 1.66. Regeneron Pharmaceuticals has a 52-week low of $325.35 and a 52-week high of $543.55. The company has a 50-day moving average price of $494.31 and a 200 day moving average price of $428.60.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported $4.17 EPS for the quarter, beating the Zacks’ consensus estimate of $2.67 by $1.50. The company had revenue of $1.47 billion during the quarter, compared to the consensus estimate of $1.36 billion. Regeneron Pharmaceuticals had a net margin of 22.05% and a return on equity of 25.58%. Regeneron Pharmaceuticals’s quarterly revenue was up 21.2% on a year-over-year basis. During the same quarter in the prior year, the firm earned $2.82 EPS. On average, analysts expect that Regeneron Pharmaceuticals will post $14.84 earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: “Regeneron Pharmaceuticals, Inc. (REGN) Receives Positive Rating from Leerink Swann” was reported by Watch List News and is the sole property of of Watch List News. If you are accessing this news story on another domain, it was illegally stolen and reposted in violation of U.S. & international copyright & trademark laws. The original version of this news story can be accessed at https://www.watchlistnews.com/regeneron-pharmaceuticals-inc-regn-receives-positive-rating-from-leerink-swann/1490011.html.

In other Regeneron Pharmaceuticals news, EVP Neil Stahl sold 8,306 shares of Regeneron Pharmaceuticals stock in a transaction dated Thursday, June 22nd. The shares were sold at an average price of $532.55, for a total transaction of $4,423,360.30. Following the completion of the transaction, the executive vice president now owns 43,950 shares in the company, valued at $23,405,572.50. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, major shareholder Sanofi bought 136,050 shares of the business’s stock in a transaction on Friday, June 2nd. The shares were acquired at an average price of $478.17 per share, with a total value of $65,055,028.50. The disclosure for this purchase can be found here. In the last three months, insiders have sold 56,922 shares of company stock worth $27,383,105. 10.40% of the stock is owned by insiders.

A number of institutional investors have recently made changes to their positions in the company. Korea Investment CORP boosted its position in shares of Regeneron Pharmaceuticals by 223.9% in the first quarter. Korea Investment CORP now owns 298 shares of the biopharmaceutical company’s stock worth $115,000 after buying an additional 206 shares during the last quarter. Fieldpoint Private Securities LLC acquired a new position in shares of Regeneron Pharmaceuticals during the second quarter worth about $130,000. Sterling Investment Advisors Ltd. boosted its position in shares of Regeneron Pharmaceuticals by 11.2% in the second quarter. Sterling Investment Advisors Ltd. now owns 278 shares of the biopharmaceutical company’s stock worth $137,000 after buying an additional 28 shares during the last quarter. FNY Managed Accounts LLC acquired a new position in shares of Regeneron Pharmaceuticals during the first quarter worth about $140,000. Finally, FNY Partners Fund LP boosted its position in shares of Regeneron Pharmaceuticals by 200.0% in the second quarter. FNY Partners Fund LP now owns 300 shares of the biopharmaceutical company’s stock worth $147,000 after buying an additional 200 shares during the last quarter. Institutional investors own 67.16% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.

The Fly

Analyst Recommendations for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.